Cover Image
市場調查報告書

B型血友病:全球臨床實驗趨勢

Hemophilia B Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 212846
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
B型血友病:全球臨床實驗趨勢 Hemophilia B Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月15日 內容資訊: 英文 125 Pages
簡介

本報告提供B型血友病相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,及G7及E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 前五名國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:B型血友病臨床實驗數量上血液疾病臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:B型血友病臨床實驗數量上血液疾病臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - B型血友病治療藥

有潛力的藥劑

最新臨床實驗新聞:B型血友病

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4559CTIDB

GlobalData's clinical trial report, "Hemophilia B Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia B clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hemophilia B to Hematological Disorders Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hemophilia B to Hematological Disorders Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Hemophilia B Therapeutics Clinical Trials 30
  • Prominent Drugs 32
  • Latest Clinical Trials News on Hemophilia B 33
  • Sep 07, 2017: Sanofi Alliance Partner Alnylam Provides Update on Fitusiran Development Program 33
  • Jul 12, 2017: New Data Demonstrate Prophylactic Treatment with IDELVION Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B 33
  • Jul 10, 2017: Sanofi Genzyme and Alnylam Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors 33
  • Jul 07, 2017: Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors 34
  • Jul 06, 2017: Sobi and Bioverativ Announces Data on Alprolix at ISTH 2017 Congress 35
  • Jul 06, 2017: Sobi and Bioverativ Announces Data on Elocta at ISTH 2017 Congress 36
  • Jun 26, 2017: Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress 36
  • Jun 26, 2017: Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model 37
  • Jun 26, 2017: Catalyst Biosciences Announces Presentation on marzeptacog alfa at the International Society on Thrombosis and Haemostasis (ISTH) Meeting in July 2017 38
  • Jun 23, 2017: Shire to present data on SHP648 at ISTH 2017 to advance the standard of care in Hemophilia 38
  • Clinical Trial Profile Snapshots 39

Appendix 123

  • Abbreviations 123
  • Definitions 123
  • Research Methodology 124
  • Secondary Research 124
  • About GlobalData 125
  • Contact Us 125
  • Source 125

List of Tables

List of Tables

  • Hemophilia B Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hemophilia B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hemophilia B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hemophilia B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hemophilia B Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hemophilia B Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hemophilia B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Hemophilia B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Hemophilia B to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 16
  • Hemophilia B Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hemophilia B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hemophilia B to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 19
  • Hemophilia B Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hemophilia B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hemophilia B Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hemophilia B Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hemophilia B Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hemophilia B Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hemophilia B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hemophilia B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Hemophilia B Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Hemophilia B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Hemophilia B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Hemophilia B Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hemophilia B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hemophilia B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hemophilia B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hemophilia B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hemophilia B Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hemophilia B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Hemophilia B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Hemophilia B to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 16
  • Hemophilia B Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hemophilia B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hemophilia B to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 19
  • Hemophilia B Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hemophilia B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hemophilia B Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hemophilia B Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hemophilia B Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hemophilia B Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hemophilia B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hemophilia B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Hemophilia B Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hemophilia B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Hemophilia B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 124
Back to Top